TrialBMJ (Clinical research ed.)2024

Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.

Katrin Schaudig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.